RxDoctor Payments Data

Cornelia Drees, MD

Epilepsy · Scottsdale, AZNPI 1144265521

Payments from drug & device makers

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$630,377in research payments, 2019–2025

Across 177 payments — averaging $3561.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Livanova USA, Inc.$472K
  • Neuropace, Inc.$158K

How this compares

Too few epilepsy providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$112,041
Medicare patients
323
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate40$81,737
NayzilamMidazolam14$23,567
BriviactBrivaracetam12$16,081
Lacosamide32$12,209
Lamotrigine ErLamotrigine26$7,789
Levetiracetam25$2,132
Levetiracetam ErLevetiracetam24$1,237
Clobazam15$619
Escitalopram Oxalate17$331
Topiramate11$238
Lamotrigine15$232
Gabapentin13$189
Clonazepam11$88

Paid to pharmacies, not to this prescriber.

Other epilepsy in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →